Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: Studies in KKA y type 2 diabetes model mice

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 4, 2012, Pages 629-633

  Kakuta, Hiroki ^a   Ohsawa, Fuminori ^a   Yamada, Shoya ^a   Makishima, Makoto ^b   Tai, Akihiro ^c   Yasui, Hiroyuki ^d   Yoshikawa, Yutaka ^d  

^a OKAYAMA UNIVERSITY   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c PREFECTURAL UNIVERSITY OF HIROSHIMA   (Japan)

^d KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Adverse effect; Glucose lowering action; Hepatomegaly; Retinoid X receptor; Triglyceride elevation; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIVER X RECEPTOR ALPHA; NET 3IB; NET 3IP; NET TMN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR ALPHA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; FEASIBILITY STUDY; GLYCEMIC CONTROL; HEPATOMEGALY; INSULIN RESISTANCE; LIVER WEIGHT; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RISK BENEFIT ANALYSIS; STRUCTURE ANALYSIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; CERCOPITHECUS AETHIOPS; CHOLESTEROL; COS CELLS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HYPOGLYCEMIC AGENTS; LIVER; MALE; MICE; ORGAN SIZE; ORPHAN NUCLEAR RECEPTORS; PPAR GAMMA; RETINOID X RECEPTORS; TRIGLYCERIDES;

EID: 84859466190     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.629     Document Type: Article

References (16)

1. Kanda S, Nakashima R, Takahashi K, Tanaka J, Ogawa J, Ogata T, Yachi M, Araki K, Ohsumi J. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models. J. Pharmacol. Sci., 111, 155-166 (2009).
2. Mitro N, Mak PA, Vargas L, Godio C, Hampton E, Molteni V, Kreusch A, Saez E. The nuclear receptor LXR is a glucose sensor. Nature, 445, 219-223 (2007).
3. Shulman AI, Larson C, Mangelsdorf DJ, Ranganathan R. Structural determinants of allosteric ligand activation in RXR heterodimers. Cell, 116, 417-429 (2004).
4. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov., 6, 793-810 (2007).
5. Lenhard JM, Lancaster ME, Paulik MA, Weiel JE, Binz JG, Sundseth SS, Gaskill BA, Lightfoot RM, Brown HR. The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. Diabetologia, 42, 545-554 (1999).
6. Standeven AM, Thacher SM, Yuan YD, Escobar M, Vuligonda V, Beard RL, Chandraratna RA. Retinoid X receptor agonist elevation of serum triglycerides in rats by potentiation of retinoic acid receptor agonist induction or by action as single agents. Biochem. Pharmacol., 62, 1501-1509 (2001).
7. Lalloyer F, Pedersen TA, Gross B, Lestavel S, Yous S, Vallez E, Gustafsson JA, Mandrup S, Fiévet C, Staels B, Tailleux A. Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver. Arterioscler. Thromb. Vasc. Biol., 29, 1488-1495 (2009).
8. Nishimaki-Mogami T, Tamehiro N, Sato Y, Okuhira K, Sai K, Kagechika H, Shudo K, Abe-Dohmae S, Yokoyama S, Ohno Y, Inoue K, Sawada J. The RXR agonists PA024 and HX630 have different abilities to activate LXR/RXR and to induce ABCA1 expression in macrophage cell lines. Biochem. Pharmacol., 76, 1006-1013 (2008).
9. Fujii S, Ohsawa F, Yamada S, Shinozaki R, Fukai R, Makishima M, Enomoto S, Tai A, Kakuta H. Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation. Bioorg. Med. Chem. Lett., 20, 5139-5142 (2010).
10. Takamatsu K, Takano A, Yakushiji N, Morohashi K, Morishita K, Matsuura N, Makishima M, Tai A, Sasaki K, Kakuta H. The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4- isopropylphenylamino moiety, NEt-3IP (RXRalpha/beta-dual agonist). ChemMedChem, 3, 780-787 (2008).
11. Ohsawa F, Morishita K, Yamada S, Makishima M, Kakuta H. Modification at the lipophilic domain of RXR agonists differentially influences activation of RXR heterodimers. ACS Med. Chem. Lett., 1, 521-525 (2010).
12. Kasuga J, Oyama T, Hirakawa Y, Makishima M, Morikawa K, Hashimoto Y, Miyachi H. Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part. Bioorg. Med. Chem. Lett., 18, 4525-4528 (2008).
13. Aoyama A, Aoyama H, Dodo K, Makishima M, Hashimoto Y, Miyachi H. LXR antagonists with a 5-substituted phenanthridin-6-one skeleton: synthesis and LXR transrepression activities of conformationally restricted carba-T0901317 analogs. Heterocycles, 76, 137-142 (2008).
14. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev., 26, 439-451 (2005).
15. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, Kadowaki T. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARγ) deficiency and PPARγ agonist improve insulin resistance. J. Biol. Chem., 276, 41245-41254 (2001).
16. Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, Castrillo A, Wilpitz DC, Mangelsdorf DJ, Collins JL, Saez E, Tontonoz P. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl. Acad. Sci. U.S.A., 100, 5419-5424 (2003).